TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Living Cell Technologies ( (AU:1AI) ) has shared an announcement.
Algorae Pharmaceuticals has signed a distribution agreement with Dr. Reddy’s Laboratories to supply the chemotherapy medicine Capecitabine to the Australian market, with the first shipment expected in December 2025. This strategic partnership is set to expand Algorae’s commercial footprint and provide a pathway to near-term revenue, while positioning the company for long-term growth and future collaborations in the oncology sector.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialization. The company uses its proprietary AI platform, AlgoraeOS, to identify synergistic drug combinations and guide dose selection for preclinical development. Algorae operates a commercialization business, AlgoraeRx, which sources, licenses, and supplies generic and specialty medicines in Australia and New Zealand. It collaborates with research institutions and industry partners to expand patient access to high-quality medicines. Algorae is publicly traded on the Australian Stock Exchange.
YTD Price Performance: 30.0%
Average Trading Volume: 2,896,219
Technical Sentiment Signal: Sell
Current Market Cap: A$21.95M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.